Imvax is pioneering a novel approach to cancer treatment through its Goldspire® immunotherapy platform, which focuses on personalized, whole tumor-derived therapies. This platform captures the complete antigen signature of a patient's tumor, allowing for a comprehensive immune response against the cancer. By utilizing patient-derived tumor cells combined with an antisense oligodeoxynucleotide (IMV-001) targeting the insulin-like growth factor type 1 receptor (IGF-1R), Imvax aims to stimulate both innate and adaptive immunity. The tumor cells are processed and placed in proprietary biodiffusion chambers (BDCs) for a short duration, during which they undergo immunogenic cell death, releasing antigens that activate the immune system.

The Goldspire® platform offers several advantages over traditional therapies, including the ability to expose the immune system to a full range of tumor antigens, potentially leading to a broader anti-tumor effect. This personalized approach minimizes off-target effects, as the immune system is trained to recognize the unique antigenic signature of the patient's tumor. Additionally, the rapid processing of tumor samples—completed in less than 24 hours—enables timely integration into existing standard care protocols. Imvax's ongoing clinical trials, particularly for its lead product candidate IGV-001 in glioblastoma, are designed to evaluate the safety and efficacy of this innovative treatment strategy.

United States

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s combination therapy uniquely captures the complete antigenic signature of a patient’s own tumor and converts it into a highly stimulatory ‘training program’ for the patient’s immune system. The comprehensive nature of this training is intended to result in both innate and adaptive immune stimulation to optimize long-term anti-tumor effects. The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer, with additional programs in other types of solid tumors.

Imvax

Company Details